Immunology and Liver

  • M. P. Manns
  • G. Paumgartner
  • U. Leuschner

Part of the Falk Symposium book series (FASS, volume 114)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Basic mechanisms of autoimmunity

    1. Front Matter
      Pages 1-1
    2. B. Arnold
      Pages 3-7
    3. D. Pessayre, V. Descatoire, P. Dansette, J. Loeper, A. Berson, M.-A. Robin
      Pages 16-34
    4. B. Ludewig, P. Aichele, R. M. Zinkernagel, H. Hengartner
      Pages 46-54
  3. Definition and spectrum of autoimmune hepatitis

    1. Front Matter
      Pages 55-55
    2. M. Nishioka
      Pages 69-81
    3. E. L. R. Cançado, G. Porta
      Pages 82-92
    4. F. Alvarez
      Pages 93-98
    5. P. Obermayer-Straub, M. P. Manns
      Pages 99-111
  4. Pathogenesis of autoimmune liver diseases

    1. Front Matter
      Pages 113-113
    2. P. T. Donaldson
      Pages 115-132
    3. D. Vergani, G. Mieli-Vergani
      Pages 133-136
    4. B. Terjung, H. J. Worman
      Pages 137-151
    5. J. Węsierska-Gądek, E. Penner
      Pages 152-163
  5. Drug and hepatitis virus induced autoimmunity

    1. Front Matter
      Pages 165-165
    2. M. Wulferink, P. Griem, E. Gleichmann
      Pages 192-206
    3. J. T. Gerlach, N. Gruener, H. Diepolder, M.-C. Jung, G. R. Pape
      Pages 207-215
    4. F. B. Bianchi, D. Zauli, M. Lenzi, F. Cassani, L. Muratori
      Pages 216-220
  6. Primary biliary cirrhosis, primary sclerosing cholangitis and overlap syndromes

    1. Front Matter
      Pages 221-221
    2. A. Tanaka, P. S. C. Leung, J. Van De Water, S. Munoz, R. L. Coppel, A. Ansari et al.
      Pages 244-256
    3. H. J. Worman, B. Terjung, J.-C. Courvalin
      Pages 257-267
    4. J. Heathcote
      Pages 288-295
    5. U. Broomé, A. Bergquist
      Pages 296-307
  7. Therapy of autoimmune liver diseases — state of the art

    1. Front Matter
      Pages 309-309
    2. R. Poupon, C. Corpechot, R. E. Poupon
      Pages 325-329
    3. U. Beuers, G. Paumgartner
      Pages 330-337
  8. Therapy of autoimmune liver diseases — the future

    1. Front Matter
      Pages 367-367
    2. V. K. Tuohy, P. M. Mathisen
      Pages 376-385
  9. Back Matter
    Pages 387-400

About this book


In 1992, the Falk Symposium No. 70 dealt with the topic `Immunology and Liver'. At that time basic mechanisms of immunology as well as immunopathogenetic mechanisms in viral and autoimmune liver diseases were discussed. Now, 7 years later, the Falk Symposium No. 114, held in Basel, Switzerland, October 20-21 1999 (Part I of the Basel Liver Week 1999), focused on immunology in autoimmune liver diseases. In the first section basic mechanisms of autoimmunity are presented, including the relevance of superantigens and the role of apoptosis. A further topic is the latest developments concerning animal models for autoimmune diseases. Recently the International Autoimmune Hepatitis Group newly defined and reclassified the syndrome of autoimmune hepatitis. Autoimmune hepatitis is now identified and studied in all parts of the world, including Asia and South America. A special variant of autoimmune hepatitis was identified as one organ manifestation of the autoimmune polyendocrine syndrome type 1, a genetic disease caused by mutations in a single transcription factor. Drug- and hepatitis-virus induced immune mediated liver diseases may serve as models for nonhepatic immune mediated disorders. DNA technology has increased our knowledge of the immunogenetic background of autoimmune liver diseases. Among the cholestatic immune mediated liver diseases, significant progress has been made concerning primary biliary cirrhosis, in particular regarding the identification of mitochondrial antigens and the characterisation of the immune reactions directed at them. The involvement of infectious agents in PBC as well as the definition of overlap syndromes is a particular focus for basic and clinical research in this area.
Concerning the therapy of autoimmune liver diseases, corticosteroids and azathioprin remain the state of the art for autoimmune hepatitis, while bile acids have become well established in treatment of primary biliary cirrhosis as well as primary sclerosing cholangitis. New drugs in the future will include topical steroids such as budesonide and new immunosuppressive agents like mofetil/mycophenolate. Liver transplantation is the treatment of choice for end stage liver diseases; all autoimmune liver diseases are among the best candidates for liver transplantation. Hopefully, new therapeutic strategies based on the results obtained from experimental models will become everyday clinical practice in the next decade. Therefore this symposium concludes with a discussion.


Antigen apoptosis autoimmune disease autoimmunity diseases gene therapy genetics hepatitis immunology liver liver disease liver transplantation proteins transplantation viral hepatitis

Editors and affiliations

  • M. P. Manns
    • 1
  • G. Paumgartner
    • 2
  • U. Leuschner
    • 3
  1. 1.Abt. Gastroenterologie/Hepatologie Zentrum Innere MedizinMedizinische Hochscule HannoverHannoverGermany
  2. 2.Medizinische Klinik IIKlinikum Grosshadern der LMU MünchenMünchenGermany
  3. 3.Abt. Gastroenterologie Zentrum der Innere MedizinKlinikum der Johann-Wolfgang-Goethe-Universität FrankfurtFrankfurtGermany

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers and Falk Foundation e.V. 2000
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-5768-4
  • Online ISBN 978-94-011-4000-3
  • Buy this book on publisher's site